Overview
Pediatric Sarcomas: Sarcomas are among the most difficult-to-treat cancers in pediatric oncology, with metastatic forms having the highest mortality. We have established genetically defined human cell-based models and genetically engineered murine models for the pediatric skeletal muscle cancer known as rhabdomyosarcoma. Using these models, we can study the causative role of certain genetic changes (e.g. chromosomal translocations and oncogenic RAS) in rhabdomyosarcoma formation and treatment resistance. Specific goals of this research program include the identification of signaling pathways corrupted in rhabdomyosarcoma, with focus on the PAX3::FOXO1 mutation and its downstream effectors and oncogenic RAS, and identification of new therapeutic targets for treatment of this childhood cancer.
Current Appointments & Affiliations
Associate Professor of Pediatrics
·
2012 - Present
Pediatrics, Hematology-Oncology,
Pediatrics
Associate Professor of Pharmacology and Cancer Biology
·
2012 - Present
Pharmacology & Cancer Biology,
Basic Science Departments
Associate Professor of Cell Biology
·
2022 - Present
Cell Biology,
Basic Science Departments
Member of the Duke Cancer Institute
·
1999 - Present
Duke Cancer Institute,
Institutes and Centers
Recent Publications
Towards directed therapy for fusion-positive rhabdomyosarcoma.
Journal Article Pharmacol Ther · December 2025 Rhabdomyosarcoma is the most common soft tissue sarcoma of childhood. The fusion-positive variant of rhabdomyosarcoma has the dubious distinction of being one of the most difficult to cure childhood cancers. Although the gene fusions PAX3::FOXO1 and PAX7:: ... Full text Link to item CiteAbstract A022-PR005: CDK8 Inhibition Releases the Muscle Differentiation Block in Fusion-Driven Alveolar Rhabdomyosarcoma
Conference Cancer Research · September 25, 2025 AbstractFunctional and chemical genomic approaches, such as the Broad Institute’s Cancer Dependency Map and PRISM (Profiling Relative Inhibition S ... Full text CitePrioritization of novel agents for further investigation in pediatric non-rhabdomyosarcoma soft tissue sarcomas: A report from the Children's Oncology Group.
Journal Article Eur J Cancer · August 26, 2025 Non-rhabdomyosarcoma soft tissue sarcoma (NRSTS) is a group of over 70 tumors that occur across the age range and account for approximately 4 % of childhood cancers. Patients with metastatic or relapsed NRSTS have a dismal prognosis. The histologic, molecu ... Full text Link to item CiteRecent Grants
Identification and targeting of essential regions of driver fusion oncoproteins in rhabdomyosarcoma
ResearchPrincipal Investigator · Awarded by V Foundation for Cancer Research · 2025 - 2030Pharmacological Sciences Training Program
Inst. Training Prgm or CMEPreceptor · Awarded by National Institutes of Health · 2025 - 2030Unified Program for Therapeutics in Children
Inst. Training Prgm or CMEPreceptor · Awarded by National Institutes of Health · 2025 - 2030View All Grants
Education, Training & Certifications
Duke University ·
1995
M.D.
Duke University ·
1993
Ph.D.